CRIS Current Research Information System

CLISSA, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.722
EU - Europa 1.641
AS - Asia 802
AF - Africa 119
SA - Sud America 4
OC - Oceania 1
Totale 4.289
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.705
GB - Regno Unito 441
IT - Italia 324
CN - Cina 304
SE - Svezia 296
VN - Vietnam 195
DE - Germania 185
SG - Singapore 163
RU - Federazione Russa 88
IN - India 73
IE - Irlanda 57
TG - Togo 46
FR - Francia 45
GR - Grecia 40
ZA - Sudafrica 34
NG - Nigeria 27
UA - Ucraina 27
EE - Estonia 24
JO - Giordania 22
CH - Svizzera 19
BE - Belgio 18
BG - Bulgaria 17
CA - Canada 17
FI - Finlandia 17
AT - Austria 14
HR - Croazia 14
IR - Iran 9
KR - Corea 9
NL - Olanda 8
PH - Filippine 6
SC - Seychelles 6
CI - Costa d'Avorio 5
TR - Turchia 4
BR - Brasile 3
HK - Hong Kong 3
IL - Israele 3
JP - Giappone 3
LB - Libano 3
LT - Lituania 3
AZ - Azerbaigian 1
BD - Bangladesh 1
EC - Ecuador 1
EG - Egitto 1
ID - Indonesia 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
PT - Portogallo 1
UZ - Uzbekistan 1
Totale 4.289
Salva come PNG Salva come JPEG
Città #
Southend 418
Chandler 199
Fairfield 180
Santa Clara 141
Ashburn 131
Singapore 125
Bologna 114
Woodbridge 92
Houston 91
Wilmington 89
Dong Ket 82
Seattle 80
Ann Arbor 78
Princeton 74
Cambridge 67
Dublin 57
Lomé 46
Beijing 44
Boardman 43
Westminster 40
Padova 37
Nanjing 36
Milan 31
Abeokuta 27
Saint Petersburg 27
Medford 24
Amman 22
New York 20
Berlin 18
Brussels 18
Jinan 18
Helsinki 17
Sofia 17
Changsha 16
Shenyang 16
Bern 15
Turin 15
Jiaxing 14
Redwood City 14
Hebei 12
Nanchang 12
Vienna 12
Bremen 10
Tappahannock 10
Florence 9
Dearborn 8
Frankfurt am Main 8
Grafing 8
Haikou 8
Norwalk 8
San Diego 8
Shanghai 8
Tianjin 8
Valsamoggia 8
Zhengzhou 7
Athens 6
Davao City 6
Falls Church 6
Hangzhou 6
Hefei 6
Jacksonville 6
Mahé 6
North York 6
Toronto 6
Abidjan 5
Bühl 5
Yubileyny 5
Amsterdam 4
Andover 4
Fuzhou 4
Guangzhou 4
Istanbul 4
Mülheim 4
Riolo Terme 4
Rome 4
Taizhou 4
Wuhan 4
Busto Arsizio 3
Faenza 3
Hong Kong 3
Kunming 3
Los Angeles 3
Merano 3
Moscow 3
Ottawa 3
Shijiazhuang 3
Taglio Di Po 3
Taiyuan 3
Zanjan 3
Brescia 2
Calderara Di Reno 2
Cesena 2
Dehradun 2
Dongguan 2
Gussago 2
Holon 2
Imola 2
Langfang 2
Lanzhou 2
Las Vegas 2
Totale 2.904
Salva come PNG Salva come JPEG
Nome #
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 220
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 219
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 199
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 156
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 147
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 147
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 139
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 136
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 135
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 134
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 131
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 129
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 129
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 127
Nuclear inositide signaling in myelodysplastic syndromes. 121
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 120
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 118
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 117
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 115
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 112
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 110
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 110
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 107
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 106
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 106
null 103
null 93
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 90
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 82
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 82
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 80
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 79
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 75
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 74
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 73
null 71
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 61
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 33
Totale 4.386
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.729
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.729
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020512 0 0 0 0 0 0 102 85 132 67 66 60
2020/2021520 100 24 5 7 23 14 16 35 50 25 9 212
2021/2022778 84 11 52 86 78 48 19 38 39 72 120 131
2022/2023898 73 132 44 115 74 67 34 92 146 9 74 38
2023/2024310 7 45 22 32 41 62 10 19 20 18 19 15
2024/2025528 38 74 74 50 184 53 55 0 0 0 0 0
Totale 4.386